Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ten-year costs of cardiovascular disease in genetically verified familial hypercholesterolaemia compared with age- and sex-matched controls.

European journal of preventive cardiology - 18 Feb 2026

Wisløff Torbjørn, Mundal Liv J, Igland Jannicke, Svendsen Karianne, Bogsrud Martin Prøven, Kristiansen Ivar Sønbø, Retterstøl Kjetil

Abstract excerpt

AIMS: Available data on economic consequences of carrying an inherited familial hypercholesterolaemia (FH) genetic variant are sparse. This study aims to explore the hospital and pharmaceutical resource use and costs associated with cardiovascular disease (CVD) in patients with genetically verified FH compared with age- and sex-matched controls during the period 2010 through 2019. METHODS AND RESULTS: We included...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiovascular Diseases
Share to Case-Control Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Costs

Share to Health Care Costs

Share to Hyperlipoproteinemia Type II

Share to Norway

Share to Registries

Share to Time Factors

Source

Identifiers

PMID: 40986654
DOI: 10.1093/eurjpc/zwaf592

Genes

FH

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ten-year costs of cardiovascular disease in genetically verified familial hypercholesterolaemia compared with age- and sex-matched controls.PMID 40986654Read ↗

Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.Semantic proximity Read ↗

Cardiovascular disease in patients with genotyped familial hypercholesterolemia in Norway during 1994-2009, a registry study.Semantic proximity Read ↗

Molecular genetic testing for autosomal dominant hypercholesterolemia in 29,449 Norwegian index patients and 14,230 relatives during the years 1993-2020.Semantic proximity Read ↗

Proprotein Convertase Subtilisin/Kexin Type 9 Gene Polymorphism (PCSK9) in Coronary Heart DiseasesSemantic proximity Read ↗

Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome.Semantic proximity Read ↗

The Treatment Pattern and Economic Burden of Homozygous Familial Hypercholesterolemia in China: A Study based on a Patient-SurveySemantic proximity Read ↗

Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands.Semantic proximity Read ↗

An evaluation of the cost-effectiveness of population genetic screening for familial hypercholesterolemia in US patients.Semantic proximity Read ↗

Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia.Semantic proximity Read ↗

Determining Cost-Saving Risk Thresholds for Statin UseSemantic proximity Read ↗

Cost-effectiveness of alternative cascade screening strategies for familial hypercholesterolemia with realistic cascade screening acceptance rates and use of high-cost drugsSemantic proximity Read ↗

Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.